William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases
Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo
Stifel Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $13
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Hold Rating, Cuts Target Price to $3
Cabaletta Bio Is Maintained at Buy by UBS
Cabaletta Bio Price Target Cut to $7.00/Share From $10.00 by UBS
Cabaletta Bio Is Maintained at Overweight by Morgan Stanley
HC Wainwright & Co. Reiterates Buy on Cabaletta Bio, Maintains $25 Price Target
Cabaletta Bio Analyst Ratings
Cabaletta Bio's Strategic Advances in Myositis Treatment Drive Buy Rating
Express News | Cabaletta Bio Inc : Morgan Stanley Cuts Target Price to $22 From $30
Express News | Cabaletta Bio, Inc. : Wells Fargo Cuts Target Price to $3 From $6
Analysts Conflicted on These Healthcare Names: Boston Scientific (BSX), Cabaletta Bio (CABA) and Eli Lilly & Co (LLY)
Cabaletta Bio Price Target Lowered to $13 From $26 at Stifel
Cabaletta Bio | 10-K: FY2024 Annual Report
Cabaletta Bio Reports Q4 EPS (65c), Consensus (63c)
Cabaletta Bio | 8-K: Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Press Release: Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Express News | Cabaletta Bio Q4 Income From Operations USD -33.785 Million